Human ES-derived cardiomyocytes regenerate non-human primate hearts

ceazon

) Z! v# \* |' o$ m6 D  K2 w0 K
: `% [) I8 O0 s4 M6 \2 [( G% k( v. D& X: K2 E
: x2 _" g6 s2 c+ H" [% Z; G
Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts
- [7 ^4 E- a; b6 M, |; r2 Q7 J4 C0 r3 {! _/ x4 Z$ G: G) G3 _
5 U9 K% Y: ~* K2 C3 @: a; n7 N

9 ]6 G/ z2 w9 bPluripotent stem cells provide a potential solution to current epidemic rates of heart failure1 by providing human cardiomyocytes to support heart regeneration2. Studies of human embryonic-stem-cell-derived cardiomyocytes (hESC-CMs) in small-animal models have shown favourable effects of this treatment. However, it remains unknown whether clinical-scale hESC-CM transplantation is feasible, safe or can provide sufficient myocardial regeneration. Here we show that hESC-CMs can be produced at a clinical scale (more than one billion cells per batch) and cryopreserved with good viability. Using a non-human primate model of myocardial ischaemia followed by reperfusion, we show that that cryopreservation and intra-myocardial delivery of one billion hESC-CMs generates extensive remuscularization of the infarcted heart. The hESC-CMs showed progressive but incomplete maturation over a 3-month period. Grafts were perfused by host vasculature, and electromechanical junctions between graft and host myocytes were present within 2 weeks of engraftment. Importantly, grafts showed regular calcium transients that were synchronized to the host electrocardiogram, indicating electromechanical coupling. In contrast to small-animal models7, non-fatal ventricular arrhythmias were observed in hESC-CM-engrafted primates. Thus, hESC-CMs can remuscularize substantial amounts of the infarcted monkey heart. Comparable remuscularization of a human heart should be possible, but potential arrhythmic complications need to be overcome.

cortex

原文

bubble_w

求原文